Clinical trials: Parkinson Disease Psychosis
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Parkinson's Disease
PET Scanning in Parkinson s Disease
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum…
- Trial name
- NCT00024622
- Testing
- O-15 Water, 18F-Fluoro-L-dopa
- Where
- United States
- Volunteers
- 502 people
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson's Disease
Psychiatric and Cognitive Manifestations of Parkinson's Disease
Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of PD…
- Trial name
- NCT00360633
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease, Psychotic Disorders
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease.
- Trial name
- NCT00125138
- Testing
- Melperone HCl
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 90 people
- Sponsor
- Lundbeck LLC
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson's Disease
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.
- Trial name
- NCT02818777
- Testing
- cannabidiol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Parkinson's Disease Psychosis
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00658567
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 123 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Dementia, Parkinson Disease
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
The primary aim of this study is to determine the safety and efficacy of quetiapine (Seroquel) for the treatment of psychosis and/or agitation in patients with primary dementia complicated by coexistent parkinsonism, or patients…
- Trial name
- NCT00043849
- Testing
- Quetiapine
- Where
- 21 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute on Aging (NIA)
Parkinson Disease
Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD). II.
- Trial name
- NCT00004826
- Testing
- clozapine
- Volunteers
- 60 people
- Sponsor
- Memorial Hospital of Rhode Island
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson Disease Psychosis
Presence Hallucination in Parkinson's Disease
Investigation on how robotically mediated sensorimotor stimulation induces and triggers presence hallucinations in patients with Parkinson disease
- Trial name
- NCT04579887
- Testing
- Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations
- Where
- 4 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- Olaf Blanke
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Neurodegenerative Diseases, Parkinson Disease
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group.
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
- Trial name
- NCT05357612
- Testing
- Pimavanserin
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Clozapine, Parkinson's Disease (PD)
Clozapine-related Immunodeficiency in Parkinsons Disease
Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia.
- Conditions
- Clozapine, Parkinson's Disease (PD), Immunodeficiency, Psychosis
- Trial name
- CLOZIDPD (NCT06634641)
- Testing
- blood test
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Healthy, Schizophrenia
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Brain cells communicate with each other by releasing chemicals called neurotransmitters. In order for brain cells to transfer information, one cell will release a neurotransmitter that will be recognized by a receptor located on…
- Trial name
- NCT00001320
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)